Skip to main content

Table 7 The minimal inhibitory concentration (MIC) distribution of ceftobiprole when tested against different clinically isolated strains in China

From: Antimicrobial activity of ceftobiprole and comparator agents when tested against gram-positive and -negative organisms collected across China (2016–2018)

Organisms (no.)

Cumulative percentage of isolates at MIC (mg/L, %)

 ≤ 0.015

0.03

0.06

0.125

0.25

0.5

1

2

4

8

16

32

64

128

 > 128

a

MRSA (55)

0.0

0.0

0.0

0.0

5.5

27.3

80.0

100.0

     

MSSA (55)

0.0

0.0

0.0

0.0

1.8

69.1

98.2

100.0

     

MRCNS (40)

10.0

10.0

10.0

10.0

12.5

40.0

87.5

95.0

100.0

    

MSCNS (40)

5.0

5.0

15.0

32.5

65.0

97.5

100.0

      

E. faecalis (24)

0.0

0.0

4.2

4.2

25.0

66.7

91.7

91.7

91.7

91.7

91.7

91.7

100.0

E. faecium (23)

0.0

0.0

0.0

0.0

0.0

4.3

8.7

17.4

17.4

17.4

17.4

17.4

100.0

S. pyogenes (13)

100.0

            

S. agalactiae (14)

100.0

            

S. mitis (12)

58.3

58.3

75.0

75.0

75.0

83.3

83.3

100.0

     

PSSP (110)

24.5

28.2

40.0

55.5

74.5

98.2

100.0

      

PISP (25)

0.0

0.0

0.0

4.0

8.0

52.0

100.0

      

PRSP (13)

0.0

0.0

0.0

0.0

0.0

53.8

84.6

92.3

92.3

92.3

92.3

100.0

 

H. influenzae (53)

71.2

76.9

76.9

82.7

86.5

96.2

100.0

      

M. catarrhalis (49)

0.0

0.0

18.4

38.8

71.4

98.0

100.0

      

E. coli (ESBL-) (49)

59.2

89.8

91.8

95.9

95.9

100.0

       

E. coli (ESBL +) (50)

0.0

0.0

0.0

0.0

4.0

4.0

4.0

4.0

6.0

8.0

8.0

8.0

100.0

b

K. pneumonia (ESBL-) (56)

80.4

87.5

98.2

98.2

98.2

98.2

98.2

98.2

98.2

98.2

98.2

98.2

100.0

K. pneumonia (ESBL +) (58)

5.2

5.2

6.9

6.9

6.9

6.9

6.9

8.6

10.3

12.1

12.1

13.8

100.0

CR-KPN (45)

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

100.0

E. cloacae (49)

40.8

49.0

49.0

57.1

61.2

61.2

63.3

67.3

67.3

69.4

69.4

69.4

100.0

E. aerogenes (55)

54.5

74.5

80.0

83.6

85.5

85.5

87.3

87.3

87.3

87.3

87.3

89.1

100.0

C. freudii (53)

50.9

58.5

64.2

64.2

66.0

69.8

71.7

71.7

71.7

71.7

71.7

73.6

100.0

P. mirabilis (52)

55.8

65.4

65.4

65.4

65.4

67.3

67.3

67.3

69.2

69.2

69.2

71.2

100.0

P. vulgaris (35)

17.1

17.1

17.1

17.1

20.0

25.7

31.4

34.3

54.3

60.0

80.0

88.6

100.0

M. morganella (53)

65.5

78.2

80.0

83.6

85.5

87.3

87.3

87.3

87.3

96.4

100.0

  

S. marcescens (53)

9.6

38.5

71.2

80.8

84.6

88.5

88.5

90.4

90.4

90.4

90.4

90.4

100.0

CS-PAE (19)

0.0

0.0

0.0

0.0

10.5

26.3

47.4

84.2

89.5

89.5

89.5

89.5

100.0

CR-PAE (19)

0.0

0.0

0.0

0.0

0.0

0.0

10.5

52.6

84.2

89.5

94.7

94.7

100.0

CS-ABA (17)

0.0

0.0

41.2

64.7

88.2

88.2

94.1

94.1

94.1

94.1

94.1

94.1

100.0

CR-ABA (19)

0.0

0.0

0.0

0.0

0.0

0.0

5.3

5.3

5.3

5.3

10.5

26.3

100.0

  1. MRSA Methicillin-resistant Staphylococcus aureus, MSSA Methicillin-susceptible Staphylococcus aureus, MRCNS Methicillin-resistant Coagulase negative Staphylococci, MSCNS Methicillin-susceptible Coagulase negative Staphylococci, PSSP Streptococcus pneumonia with MIC of Penicillin ≤ 2 mg/L, PISP Streptococcus pneumonia with MIC of Penicillin = 4 mg/L, PRSP Streptococcus pneumonia with MIC of Penicillin ≥ 8 mg/L, ESBL- Extended spectrum β-Lactamases negative, ESBL + Extended spectrum β-Lactamases positive, CR-KPN Carbapenem-resistant Klebsiella pneumonia, CS-PAE Carbapenem-susceptible Pseudomonas aeruginosa, CR-PAE Carbapenem-resistant Pseudomonas aeruginosa, CS-ABA Carbapenem-susceptible Acinetobacter baumanni, CR-ABA Carbapenem-resistant Acinetobacter baumanni